Conflict Of Interest Reform Fight Reignites Following Panel Revelations
This article was originally published in The Tan Sheet
Executive Summary
Advisory committee conflict of interest reform draws increased attention in the wake of concerns raised about a recent Reproductive Health panel meeting.
You may also be interested in...
FDA Advisory Committees Would Get Patient Influence Under Hagan Bill
Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.